analysis of consolidated financial position as at 30 June 2017 ..................................................................... 3 The analysis of operating result for six months

the capital invested in the subsidiary, SSK, at the cost price where the term of the payment of share price is limited within 2.5 years. The Company, therefore, recognized the loss from the calculation

% of paid up capital, Total investment 50 Millions baht. The acquisition of BS Myco Biotech shares will result in the BS Myco Biotech being a subsidiary of the Company. The Company signed the share

According to the resolution of the meeting of the Board of Directors No. 6/2017 of Rajthanee Hospital Public Company Limited (the “Company”) held on 10 November 2017, approving the reviewed consolidated

Seamico Securities Public Company Limited (“The Company”) would like to report operating result that has been examined by our auditor for the year ended December 31, 2017 as follows: The consolidated

Director Ratio Analysis : Consolidated Financial Statements 1Q 1Q Unit : THB million 2019 2018 Returns (%) Return on Assets * 4.4% 3.1% Return on Equity * 5.6% 3.6% Working Capital Management (Days) Trade

Indorama Ventures Public Company Limited for the second quarter ended June 30, 2020 We are pleased to submit: 1. Consolidated and Company only Quarterly Review of Financial Statements for the second quarter

Indorama Ventures Public Company Limited for the first quarter ended March 31, 2020 We are pleased to submit: 1. Consolidated and Company only Quarterly Review of Financial Statements for the first quarter

Microsoft Word - Ref FPI.012.2018.doc Ref. FPI.012/2018 26 April 2018 Subject Acquisition of up to 40% shares of total paid-up capital in TSE Overseas Group Company Limited To President The Stock

Electronics PCL has the pleasure of submitting the operating results of the Company and its subsidiaries ("the Group") for the second quarter of 2018 based on reviewed consolidated financial statements for the